Is vascular endothelial growth factor D expression a potential biomarker of bevacizumab benefit in colorectal cancer?
The predictive value of VEGF-D expression for bevacizumab may depend on the chemotherapy backbone used. Further evaluation is required before clinical utilisation.
Outcomes after pancreatic resection can be improved by increasing the success rate of epidural anesthesia.